
The Oncomine Dx Express Test for oncology biomarker profiling

A patient's tumor profile has the potential to guide precision oncology care, but only if the results are reported in time. Now, with the lon Torrent™ Oncomine™ Dx Express Test on the lon Torrent™ Genexus™ Dx System*, you can perform fast NGS testing for clinically relevant biomarkers in as little as 24 hours.



EGFR

The time to informed treatment decisions is critical for oncology patients



24

as little as 24 hours turnaround time from sample to clinically relevant biomarker report

KRAS



Patients everywhere should be routinely tested for clinically relevant biomarkers

46 genes

including EGFR, ALK, BRAF, ROS1, RET, KRAS, PIK3CA, NTRK, MET, IDH1 and ERBB2, among others


100%

clinically relevant biomarkers for NSCLC and majority for other solid tumors^{1,2}

100% clinically relevant biomarkers = unique biomarkers that have an ESCAT level of IA, IB, or IC; majority = 86%, BRCA1/2 and MSI-H are not covered by the Oncomine Dx Express Test. 2 Mosele F. et al. (2020) Ann Oncol 31:1491

Even small biopsies should generate results

10 ng
minimum
sample input



~95%
sample
success rate



REL

Automation and ease of use are key to enabling implementation of NGS workflows in every laboratory

2 instruments

software and report linking biomarkers with relevant evidence from approved therapies, guidelines, and clinical trials

2 touchpoints

20



supplier and team to support you

OS1